| Dr Paul-thomas Tremoulet, MD | |
|
354 Santa Fe Dr, Encinitas, CA 92024-5142 | |
| (760) 230-2251 | |
| Not Available |
| Full Name | Dr Paul-thomas Tremoulet |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 24 Years |
| Location | 354 Santa Fe Dr, Encinitas, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528060100 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | A76789 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Scripps Memorial Hospital - Encinitas | Encinitas, CA | Hospital |
| Scripps Green Hospital | La jolla, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Encinitas Emergency Medicine, Inc. | 1951711357 | 33 |
| Scripps Health | 9234033853 | 1362 |
News Archive
Researchers from the Byers Eye Institute at Stanford University have found a way to use artificial intelligence to fight a complication of diabetes that affects the eyes. This advance has the potential to reduce the worldwide rate of vision loss due to diabetes.
Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2013. For the first quarter of 2013, Rigel reported a net loss of $25.6 million, or $0.29 per share, compared to a net loss of $23.2 million, or $0.32 per share, in the first quarter of 2012. Weighted average shares outstanding for the first quarters of 2013 and 2012 were 87.1 million and 71.4 million, respectively.
Precision Therapeutics, Inc., a life science company that develops personalized medicine products for individualizing cancer care, today announced that a clinical study which demonstrates the feasibility of the ChemoFx chemoresponse assay to identify patients unlikely to respond to first-line therapy has been accepted for presentation at the 2013 Annual Meeting of the Western Association of Gynecologic Oncologists.
Changes in farming practices over the last 50 years have resulted in decreased agro-diversity which, in turn, has resulted in decreased dietary diversity. The significant impact of this change in dietary richness on human health is the topic of an insightful perspective in Molecular Metabolism by Mark Heiman, MicroBiome Therapeutics and Frank Greenway, Pennington Biomedical Research Center
› Verified 8 days ago
| Entity Name | Scripps Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881636108 PECOS PAC ID: 9234033853 Enrollment ID: O20031124000822 |
News Archive
Researchers from the Byers Eye Institute at Stanford University have found a way to use artificial intelligence to fight a complication of diabetes that affects the eyes. This advance has the potential to reduce the worldwide rate of vision loss due to diabetes.
Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2013. For the first quarter of 2013, Rigel reported a net loss of $25.6 million, or $0.29 per share, compared to a net loss of $23.2 million, or $0.32 per share, in the first quarter of 2012. Weighted average shares outstanding for the first quarters of 2013 and 2012 were 87.1 million and 71.4 million, respectively.
Precision Therapeutics, Inc., a life science company that develops personalized medicine products for individualizing cancer care, today announced that a clinical study which demonstrates the feasibility of the ChemoFx chemoresponse assay to identify patients unlikely to respond to first-line therapy has been accepted for presentation at the 2013 Annual Meeting of the Western Association of Gynecologic Oncologists.
Changes in farming practices over the last 50 years have resulted in decreased agro-diversity which, in turn, has resulted in decreased dietary diversity. The significant impact of this change in dietary richness on human health is the topic of an insightful perspective in Molecular Metabolism by Mark Heiman, MicroBiome Therapeutics and Frank Greenway, Pennington Biomedical Research Center
› Verified 8 days ago
| Entity Name | Pacific Emergency Providers A Prof Corp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497790539 PECOS PAC ID: 1557327608 Enrollment ID: O20041209000658 |
News Archive
Researchers from the Byers Eye Institute at Stanford University have found a way to use artificial intelligence to fight a complication of diabetes that affects the eyes. This advance has the potential to reduce the worldwide rate of vision loss due to diabetes.
Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2013. For the first quarter of 2013, Rigel reported a net loss of $25.6 million, or $0.29 per share, compared to a net loss of $23.2 million, or $0.32 per share, in the first quarter of 2012. Weighted average shares outstanding for the first quarters of 2013 and 2012 were 87.1 million and 71.4 million, respectively.
Precision Therapeutics, Inc., a life science company that develops personalized medicine products for individualizing cancer care, today announced that a clinical study which demonstrates the feasibility of the ChemoFx chemoresponse assay to identify patients unlikely to respond to first-line therapy has been accepted for presentation at the 2013 Annual Meeting of the Western Association of Gynecologic Oncologists.
Changes in farming practices over the last 50 years have resulted in decreased agro-diversity which, in turn, has resulted in decreased dietary diversity. The significant impact of this change in dietary richness on human health is the topic of an insightful perspective in Molecular Metabolism by Mark Heiman, MicroBiome Therapeutics and Frank Greenway, Pennington Biomedical Research Center
› Verified 8 days ago
| Entity Name | Emergency Medicine Group Of Encinitas, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902805179 PECOS PAC ID: 7618929381 Enrollment ID: O20050210000997 |
News Archive
Researchers from the Byers Eye Institute at Stanford University have found a way to use artificial intelligence to fight a complication of diabetes that affects the eyes. This advance has the potential to reduce the worldwide rate of vision loss due to diabetes.
Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2013. For the first quarter of 2013, Rigel reported a net loss of $25.6 million, or $0.29 per share, compared to a net loss of $23.2 million, or $0.32 per share, in the first quarter of 2012. Weighted average shares outstanding for the first quarters of 2013 and 2012 were 87.1 million and 71.4 million, respectively.
Precision Therapeutics, Inc., a life science company that develops personalized medicine products for individualizing cancer care, today announced that a clinical study which demonstrates the feasibility of the ChemoFx chemoresponse assay to identify patients unlikely to respond to first-line therapy has been accepted for presentation at the 2013 Annual Meeting of the Western Association of Gynecologic Oncologists.
Changes in farming practices over the last 50 years have resulted in decreased agro-diversity which, in turn, has resulted in decreased dietary diversity. The significant impact of this change in dietary richness on human health is the topic of an insightful perspective in Molecular Metabolism by Mark Heiman, MicroBiome Therapeutics and Frank Greenway, Pennington Biomedical Research Center
› Verified 8 days ago
| Entity Name | Encinitas Emergency Medicine, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598362568 PECOS PAC ID: 1951711357 Enrollment ID: O20201112002457 |
News Archive
Researchers from the Byers Eye Institute at Stanford University have found a way to use artificial intelligence to fight a complication of diabetes that affects the eyes. This advance has the potential to reduce the worldwide rate of vision loss due to diabetes.
Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2013. For the first quarter of 2013, Rigel reported a net loss of $25.6 million, or $0.29 per share, compared to a net loss of $23.2 million, or $0.32 per share, in the first quarter of 2012. Weighted average shares outstanding for the first quarters of 2013 and 2012 were 87.1 million and 71.4 million, respectively.
Precision Therapeutics, Inc., a life science company that develops personalized medicine products for individualizing cancer care, today announced that a clinical study which demonstrates the feasibility of the ChemoFx chemoresponse assay to identify patients unlikely to respond to first-line therapy has been accepted for presentation at the 2013 Annual Meeting of the Western Association of Gynecologic Oncologists.
Changes in farming practices over the last 50 years have resulted in decreased agro-diversity which, in turn, has resulted in decreased dietary diversity. The significant impact of this change in dietary richness on human health is the topic of an insightful perspective in Molecular Metabolism by Mark Heiman, MicroBiome Therapeutics and Frank Greenway, Pennington Biomedical Research Center
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Paul-thomas Tremoulet, MD Po Box 910448, San Diego, CA 92191-0448 Ph: (858) 552-9272 | Dr Paul-thomas Tremoulet, MD 354 Santa Fe Dr, Encinitas, CA 92024-5142 Ph: (760) 230-2251 |
News Archive
Researchers from the Byers Eye Institute at Stanford University have found a way to use artificial intelligence to fight a complication of diabetes that affects the eyes. This advance has the potential to reduce the worldwide rate of vision loss due to diabetes.
Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2013. For the first quarter of 2013, Rigel reported a net loss of $25.6 million, or $0.29 per share, compared to a net loss of $23.2 million, or $0.32 per share, in the first quarter of 2012. Weighted average shares outstanding for the first quarters of 2013 and 2012 were 87.1 million and 71.4 million, respectively.
Precision Therapeutics, Inc., a life science company that develops personalized medicine products for individualizing cancer care, today announced that a clinical study which demonstrates the feasibility of the ChemoFx chemoresponse assay to identify patients unlikely to respond to first-line therapy has been accepted for presentation at the 2013 Annual Meeting of the Western Association of Gynecologic Oncologists.
Changes in farming practices over the last 50 years have resulted in decreased agro-diversity which, in turn, has resulted in decreased dietary diversity. The significant impact of this change in dietary richness on human health is the topic of an insightful perspective in Molecular Metabolism by Mark Heiman, MicroBiome Therapeutics and Frank Greenway, Pennington Biomedical Research Center
› Verified 8 days ago
Owen Bowers, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 354 Santa Fe Dr, Encinitas, CA 92024 Phone: 760-230-2251 Fax: 760-230-2253 | |
Paul Burbank Dohrenwend, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 354 Santa Fe Dr, Encinitas, CA 92024 Phone: 760-230-2251 Fax: 760-230-2253 | |
Dr. Matthew Kurlan, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 519 Encinitas Blvd., Suite 106, Encinitas, CA 92024 Phone: 760-230-2727 | |
Dr. Tania Robertson, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 354 Santa Fe Dr, Encinitas, CA 92024 Phone: 760-230-2251 Fax: 760-230-2253 | |
Dr. Neal J. Aaron, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 354 Santa Fe Dr, Department Of Emergency Medicine, Encinitas, CA 92024 Phone: 760-230-2251 Fax: 760-230-2253 | |
James Andrew Garvey Iv, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 354 Santa Fe Dr, Emergency Department, Encinitas, CA 92024 Phone: 760-230-2251 Fax: 760-230-2253 | |
Linette Faye Williamson, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 227 N El Camino Real, Suite 106, Encinitas, CA 92024 Phone: 760-436-5000 Fax: 760-436-9700 |